Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Short Interest Down 45.8% in October

Neuphoria Therapeutics Inc. (NASDAQ:NEUP) was the target of a significant decrease in short interest in October. As of October 15th, there was short interest totaling 13,600 shares, a decrease of 45.8% from the September 30th total of 25,100 shares. Based on an average trading volume of 1,420,000 shares, the short-interest ratio is presently 0.0 days. Currently, 0.8% of the shares of the company are short sold. Currently, 0.8% of the shares of the company are short sold. Based on an average trading volume of 1,420,000 shares, the short-interest ratio is presently 0.0 days.

Insider Activity at Neuphoria Therapeutics

In other Neuphoria Therapeutics news, major shareholder Lynx1 Capital Management Lp purchased 639,110 shares of the firm’s stock in a transaction that occurred on Tuesday, October 21st. The shares were acquired at an average cost of $5.14 per share, for a total transaction of $3,285,025.40. Following the completion of the purchase, the insider owned 875,328 shares of the company’s stock, valued at approximately $4,499,185.92. The trade was a 270.56% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.69% of the company’s stock.

Neuphoria Therapeutics Stock Down 3.9%

Shares of Neuphoria Therapeutics stock opened at $4.40 on Friday. The company has a market capitalization of $10.38 million, a price-to-earnings ratio of 0.83 and a beta of 0.59. Neuphoria Therapeutics has a 12-month low of $2.16 and a 12-month high of $21.40. The firm’s 50-day moving average price is $11.93 and its two-hundred day moving average price is $8.47.

Neuphoria Therapeutics (NASDAQ:NEUP) last announced its quarterly earnings data on Monday, September 29th. The company reported ($5.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($5.23). The business had revenue of ($0.01) million for the quarter. On average, sell-side analysts expect that Neuphoria Therapeutics will post -1.56 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on NEUP shares. Wall Street Zen upgraded shares of Neuphoria Therapeutics to a “hold” rating in a research note on Saturday, July 26th. Maxim Group upped their price target on shares of Neuphoria Therapeutics from $18.00 to $35.00 and gave the company a “buy” rating in a research note on Thursday, September 11th. Weiss Ratings downgraded shares of Neuphoria Therapeutics from a “hold (c-)” rating to a “sell (d-)” rating in a research note on Wednesday, October 8th. Finally, HC Wainwright restated a “buy” rating and issued a $21.00 price target on shares of Neuphoria Therapeutics in a research note on Tuesday, August 26th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $28.00.

Neuphoria Therapeutics Company Profile

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor.